Enovis Co. (NYSE:ENOV) Stake Cut by Artemis Investment Management LLP

Artemis Investment Management LLP lessened its holdings in shares of Enovis Co. (NYSE:ENOV) by 1.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 491,752 shares of the company’s stock after selling 9,711 shares during the quarter. Artemis Investment Management LLP owned approximately 0.90% of Enovis worth $21,170,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in ENOV. Diamond Hill Capital Management Inc. grew its position in Enovis by 14.5% during the second quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company’s stock valued at $125,929,000 after purchasing an additional 352,116 shares in the last quarter. DAVENPORT & Co LLC grew its holdings in shares of Enovis by 5.5% during the 1st quarter. DAVENPORT & Co LLC now owns 1,982,452 shares of the company’s stock valued at $123,804,000 after acquiring an additional 103,027 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Enovis by 78.6% in the second quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock worth $68,337,000 after acquiring an additional 665,208 shares during the last quarter. Magnetar Financial LLC increased its stake in shares of Enovis by 66.7% in the second quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company’s stock worth $49,937,000 after acquiring an additional 442,051 shares during the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Enovis by 2.5% during the first quarter. Principal Financial Group Inc. now owns 849,023 shares of the company’s stock worth $53,022,000 after acquiring an additional 20,720 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on ENOV shares. JPMorgan Chase & Co. dropped their target price on Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Evercore ISI dropped their price objective on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a report on Tuesday, October 1st. Needham & Company LLC cut their price objective on shares of Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Finally, JMP Securities started coverage on shares of Enovis in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 target price for the company. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $67.89.

Enovis Trading Down 2.0 %

Shares of ENOV stock opened at $38.83 on Wednesday. Enovis Co. has a 12 month low of $38.27 and a 12 month high of $65.03. The company has a market cap of $2.13 billion, a PE ratio of -25.89 and a beta of 1.91. The company has a quick ratio of 1.08, a current ratio of 2.26 and a debt-to-equity ratio of 0.40. The business’s 50 day moving average is $43.54 and its two-hundred day moving average is $48.28.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.03. The business had revenue of $525.20 million for the quarter, compared to analyst estimates of $525.99 million. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. Enovis’s revenue was up 22.6% compared to the same quarter last year. During the same period last year, the business posted $0.61 EPS. Equities analysts predict that Enovis Co. will post 2.7 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.